scholarly journals Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis

2010 ◽  
Vol 53 (2) ◽  
pp. 195-203 ◽  
Author(s):  
LiGuo Zhang ◽  
Eric Meissner ◽  
JianZhu Chen ◽  
LiShan Su
2011 ◽  
Vol 9 (8) ◽  
pp. 595-605 ◽  
Author(s):  
Rachel V. Duyne ◽  
Aarthi Narayanan ◽  
Kylene K.-Hall ◽  
Mohammed Saifuddin ◽  
Leonard Shultz ◽  
...  

Author(s):  
Tynisha Thomas ◽  
Kieran Seay ◽  
Jian Hua Zheng ◽  
Cong Zhang ◽  
Christina Ochsenbauer ◽  
...  

Viruses ◽  
2015 ◽  
Vol 7 (3) ◽  
pp. 1373-1390 ◽  
Author(s):  
Eri Yamada ◽  
Rokusuke Yoshikawa ◽  
Yusuke Nakano ◽  
Naoko Misawa ◽  
Yoshio Koyanagi ◽  
...  

2021 ◽  
Author(s):  
Leo Holguin ◽  
Liliana Echavarria ◽  
John C. Burnetta

Humanized mouse models are based on the engraftment of human cells in immunodeficient mouse strains, most notably the NSG strain. Most used models have a major limitation in common, the development of graft-versus-host disease (GVHD). GVHD not only introduces variabilities into the research data but also leads to animal welfare concerns. A new mouse strain, B6.129S-Rag2 tm1Fwa CD47 tm1Fpl Il2rg tm1Wjl /J which lacks Rag1, IL2rg, and CD47 (triple knockout or TKO), is resistant to GVHD development. We transplanted TKO mice with human peripheral blood mononuclear cells (PBMCs) to establish a new humanized PBMC (hu-PBMC) mouse model. A cohort of these mice was infected with HIV-1 and monitored for plasma HIV viremia and CD4 + T cell depletion. The onset and progression of GVHD were monitored by clinical signs. This study demonstrates that TKO mice transplanted with human PBMCs support engraftment of human immune cells in primary and secondary lymphoid tissues, rectum, and brain. Moreover, the TKO hu-PBMC model supports HIV-1 infection via intraperitoneal, rectal, or vaginal routes, as confirmed by robust plasma HIV viremia and CD4 + T cell depletion. Lastly, TKO mice showed a delayed onset of GVHD clinical signs (∼28 days) and exhibited significant decreases in plasma levels of TNFβ. Based on these results, the TKO hu-PBMC mouse model not only supports humanization and HIV-1 infection but also has a delayed onset of GVHD development, making this model a valuable tool in HIV research. Importance Currently, there is no cure or vaccine for HIV infection, thus continued research is needed to end the HIV pandemic. While many animal models are used in HIV research, none is used more than the humanized mouse model. A major limitation with current humanized mouse models is the development of graft-versus-host disease (GVHD). Here, we show a novel humanized-PBMC mouse model that has a delayed onset GVHD development and supports and models HIV infection comparable to well-established humanized mouse models.


2012 ◽  
Vol 9 (3) ◽  
pp. 237-244 ◽  
Author(s):  
Liguo Zhang ◽  
Lishan Su

2014 ◽  
Vol 21 (3) ◽  
pp. 301-309 ◽  
Author(s):  
Jenna B. Honeycutt ◽  
Patricia A. Sheridan ◽  
Glenn K. Matsushima ◽  
J. Victor Garcia

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 776
Author(s):  
Kazutaka Terahara ◽  
Ryutaro Iwabuchi ◽  
Yasuko Tsunetsugu-Yokota

A variety of humanized mice, which are reconstituted only with human hematopoietic stem cells (HSC) or with fetal thymus and HSCs, have been developed and widely utilized as in vivo animal models of HIV-1 infection. The models represent some aspects of HIV-mediated pathogenesis in humans and are useful for the evaluation of therapeutic regimens. However, there are several limitations in these models, including their incomplete immune responses and poor distribution of human cells to the secondary lymphoid tissues. These limitations are common in many humanized mouse models and are critical issues that need to be addressed. As distinct defects exist in each model, we need to be cautious about the experimental design and interpretation of the outcomes obtained using humanized mice. Considering this point, we mainly characterize the current conventional humanized mouse reconstituted only with HSCs and describe past achievements in this area, as well as the potential contributions of the humanized mouse models for the study of HIV pathogenesis and therapy. We also discuss the use of various technologies to solve the current problems. Humanized mice will contribute not only to the pre-clinical evaluation of anti-HIV regimens, but also to a deeper understanding of basic aspects of HIV biology.


2015 ◽  
Vol 31 (11) ◽  
pp. 583-594 ◽  
Author(s):  
Michael F. Good ◽  
Michael T. Hawkes ◽  
Stephanie K. Yanow

Sign in / Sign up

Export Citation Format

Share Document